A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
    Varier, Raghu U.
    Biltaji, Eman
    Smith, Kenneth J.
    Roberts, Mark S.
    Jensen, M. Kyle
    LaFleur, Joanne
    Nelson, Richard E.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2015, 36 (04): : 438 - 444
  • [32] A COMPARISON OF THE COST-EFFECTIVENESS OF FIDAXOMICIN, METRONIDAZOLE, AND VANCOMYCIN, IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASE
    Madkour, N.
    Bounthavong, M.
    Hsu, D., I
    VALUE IN HEALTH, 2012, 15 (04) : A138 - A139
  • [33] Frequency and Impact of Clostridium Difficile Infection (CDI) in Hospitalized Patients with Cirrhosis
    Reddy, K. Rajender
    Tandon, Puneeta
    O'Leary, Jacqueline G.
    Wong, Florence
    Garcia-Tsao, Guadalupe
    Kamath, Patrick S.
    Lai, Jennifer Cindy
    Biggins, Scott W.
    Thuluvath, Paul J.
    Fallon, Michael B.
    Vargas, Hugo E.
    Subramanian, Ram M.
    Thacker, Leroy R.
    Bajaj, Jasmohan S.
    HEPATOLOGY, 2018, 68 : 1336A - 1337A
  • [34] Cost-effectiveness analysis of the first-line therapies for nicotine dependence
    Cornuz, J
    Pinget, C
    Gilbert, A
    Paccaud, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (03) : 201 - 206
  • [35] Cost-effectiveness analysis of the first-line therapies for nicotine dependence
    Jacques Cornuz
    Christophe Pinget
    Allison Gilbert
    Fred Paccaud
    European Journal of Clinical Pharmacology, 2003, 59 : 201 - 206
  • [36] A BUDGET IMPACT ANALYSIS OF FIDAXOMICIN FOR THE MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION IN THE UNITED STATES
    Jiang, Y.
    Obi, E. N.
    Sears, P. S.
    Sarpong, E.
    VALUE IN HEALTH, 2020, 23 : S144 - S145
  • [37] Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis
    Konijeti, Gauree G.
    Sauk, Jenny
    Shrime, Mark G.
    Gupta, Meera
    Ananthakrishnan, Ashwin N.
    CLINICAL INFECTIOUS DISEASES, 2014, 58 (11) : 1507 - 1514
  • [38] COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL
    Silva, F.
    Lobo, I
    Pereira, R.
    Jiang, Y.
    Marcella, S.
    VALUE IN HEALTH, 2018, 21 : S226 - S226
  • [39] Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease
    You, Joyce H. S.
    Jiang, Xinchan
    Lee, Wally H.
    Chan, Paul K. S.
    Ng, Siew C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (09) : 1515 - 1523
  • [40] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
12345